Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
0(0%)
Results Posted
67%(2 trials)

Phase Distribution

Ph phase_1
2
50%
Ph phase_3
2
50%

Phase Distribution

2

Early Stage

0

Mid Stage

2

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
2(50.0%)
Phase 3Large-scale testing
2(50.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(3)
Other(1)

Detailed Status

Completed3
unknown1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (50.0%)
Phase 32 (50.0%)

Trials by Status

completed375%
unknown125%

Recent Activity

0 active trials
Showing 4 of 4
completedphase_3

A Study to Compare Efficacy and Safety of CT-P47 and RoActemra in Patients With Rheumatoid Arthritis

NCT05489224
completedphase_3

MSB11456 in Participants With Moderately to Severely Active Rheumatoid Arthritis

NCT04512001
unknownphase_1

A Study to Compare the Pharmacokinetics and Safety of CT-P47 and RoActemra in Healthy Subjects

NCT05188378
completedphase_1

Pharmacokinetics/Pharmacodynamics (PK/PD) Equivalence Study of MSB11456

NCT03282851

Clinical Trials (4)

Showing 4 of 4 trials
NCT05489224Phase 3

A Study to Compare Efficacy and Safety of CT-P47 and RoActemra in Patients With Rheumatoid Arthritis

Completed
NCT04512001Phase 3

MSB11456 in Participants With Moderately to Severely Active Rheumatoid Arthritis

Completed
NCT05188378Phase 1

A Study to Compare the Pharmacokinetics and Safety of CT-P47 and RoActemra in Healthy Subjects

Unknown
NCT03282851Phase 1

Pharmacokinetics/Pharmacodynamics (PK/PD) Equivalence Study of MSB11456

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4